Monogenic disease with epilepsy

Monogenic disease with epilepsy (Orphanet code 166472) is a broad classification category within Orphanet that encompasses a large and heterogeneous group of genetic disorders in which epilepsy is a prominent clinical feature and is caused by pathogenic variants in a single gene. This grouping includes hundreds of distinct conditions such as Dravet syndrome, various forms of progressive myoclonus epilepsy, tuberous sclerosis complex, KCNQ2-related epilepsy, SCN1A-related disorders, CDKL5 deficiency disorder, and many others. These conditions primarily affect the central nervous system, leading to recurrent seizures of various types, and may also involve intellectual disability, developmental delay, movement disorders, and behavioral abnormalities depending on the specific underlying genetic cause. Because this is a classification group rather than a single disease entity, the clinical presentation varies enormously. Some monogenic epilepsies present in the neonatal period with severe encephalopathy, while others may not manifest until childhood or adolescence. Affected body systems can extend beyond the brain to include the skin, kidneys, eyes, heart, and musculoskeletal system depending on the specific diagnosis. Inheritance patterns span the full range including autosomal dominant, autosomal recessive, X-linked, and de novo mutations. Treatment approaches depend on the specific underlying genetic diagnosis. Anti-seizure medications remain the cornerstone of management, though responsiveness varies widely. Some conditions have targeted or precision therapies (e.g., everolimus for tuberous sclerosis complex, stiripentol for Dravet syndrome, or ketogenic diet for GLUT1 deficiency syndrome). Genetic testing, including gene panels and whole exome/genome sequencing, is essential for establishing a precise molecular diagnosis, which increasingly guides treatment selection and prognostic counseling.

Common questions about Monogenic disease with epilepsy